Maurizio Averna

List of Publications by Year in Descending Order

259 papers	11,793 citations	45 h-index	102 g-index
286 ext. papers	13,819 ext. citations	5.2 avg, IF	5.58 L-index

#	Paper	IF	Citations
259	Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.. *Nutrition, Metabolism and Cardiovascular Diseases*, **2022**,	4.5	1
258	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
257	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. *Heart Failure Clinics* , **2022**, 18, 177-188	3.3	4
256	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.. *Atherosclerosis*, **2022**, 347, 63-67	3.1	0
255	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.. *Journal of the American Heart Association*, **2022**, e023668	6	2
254	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.. *Archives of Medical Science*, **2022**, 18, 285-292	2.9	0
253	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. *Journal of Internal Medicine*, **2021**, 290, 116-128	10.8	11
252	DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network analysis. *PLoS ONE*, **2021**, 16, e0247402	3.7	
251	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. *Life*, **2021**, 11,	3	2
250	Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. *Internal Medicine Journal*, **2021**, 51, 585-590	1.6	0
249	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. *Atherosclerosis*, **2021**, 325, 99-109	3.1	22
248	rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 1542-1547	4.5	0
247	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. *Endocrine*, **2021**, 71, 344-350	4	4
246	Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 137-144	4.5	2
245	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. *European Heart Journal*, **2021**,	9.5	35
244	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. *Atherosclerosis Plus*, **2021**, 43, 7-9		1
243	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. *Orphanet Journal of Rare Diseases*, **2021**, 16, 381	4.2	1

242	Resistive index of ophthalmic artery as an imaging biomarker of hypertension-related vascular and kidney damage. *Biomarkers in Medicine*, **2021**, 15, 1155-1166	2.3	1
241	Automated untargeted stable isotope assisted lipidomics of liver cells on high glucose shows alteration of sphingolipid kinetics. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158656	5	1
240	Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regulated at the transcriptional level. *Journal of Diabetes and Metabolic Disorders*, **2020**, 19, 363-371	2.5	0
239	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. *European Journal of Preventive Cardiology*, **2020**,	3.9	2
238	Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. *Current Medicinal Chemistry*, **2020**, 27, 3773-3783	4.3	2
237	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. *Atherosclerosis Supplements*, **2020**, 42, e35-e40	1.7	1
236	Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. *Atherosclerosis*, **2020**, 308, 32-38	3.1	3
235	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. *European Journal of Preventive Cardiology*, **2020**,	3.9	5
234	NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-and LXR agonists. *Molecular and Cellular Biochemistry*, **2020**, 473, 247-262	4.2	5
233	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. *Atherosclerosis*, **2020**, 312, 72-78	3.1	7
232	Mutation in candidate genes account for a small minority of hypobetalipoproteinemias and NGS analysis support polygenicity in mutation-negative patients. *Atherosclerosis*, **2020**, 315, e45	3.1	
231	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
230	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study. *Atherosclerosis*, **2020**, 292, 209-214	3.1	4
229	Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 822-829	4.5	12
228	Is echocardiography mandatory for patients with chronic kidney disease?. *Internal and Emergency Medicine*, **2019**, 14, 923-929	3.7	3
227	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. *Journal of Clinical Lipidology*, **2019**, 13, 735-743	4.9	1
226	Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 1068-1076	4.5	6
225	Resting Energy Expenditure and Substrate Oxidation in Malnourished Patients With Type 1 Glycogenosis. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5566-5572	5.6	

224	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. *Atherosclerosis*, **2018**, 271, 120-127	3.1	22
223	An irregular atrial tachycardia : What is the underlying mechanism?. *Netherlands Heart Journal*, **2018** , 26, 102-103	2.2	
222	Lipoprotein-associated phospholipase A activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 517-523	4.5	5
221	Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. *Journal of the American College of Cardiology*, **2018**, 71, 279-288	15.1	30
220	An irregular atrial tachycardia : What is the underlying mechanism?. *Netherlands Heart Journal*, **2018** , 26, 106-108	2.2	
219	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. *Internal and Emergency Medicine*, **2018**, 13, 651-660	3.7	9
218	Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred. *Journal of Clinical Lipidology*, **2018**, 12, 145-151	4.9	7
217	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. *Cardiovascular Research*, **2018**, 114, 1595-1604	9.9	8
216	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". *Atherosclerosis*, **2018**, 275, 265-272	3.1	69
215	Liver and Statins: A Critical Appraisal of the Evidence. *Current Medicinal Chemistry*, **2018**, 25, 5835-5846	4.3	12
214	Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis. *Frontiers in Physiology*, **2018**, 9, 1222	4.6	8
213	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. *Atherosclerosis*, **2018**, 277, 413-418	3.1	35
212	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. *Data in Brief*, **2018**, 21, 1334-1336	1.2	3
211	Diabetes and aortic root dimension: A controversial subject. *International Journal of Cardiology*, **2018**, 264, 190	3.2	
210	Diagnostic algorithm for familial chylomicronemia syndrome. *Atherosclerosis Supplements*, **2017**, 23, 1-7	1.7	69
209	Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. *Journal of Clinical Lipidology*, **2017**, 11, 272-281.e8	4.9	15
208	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. *American Heart Journal*, **2017**, 189, 120-127	4.9	6
207	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. *Advances in Therapy*, **2017**, 34, 1200-1210	4.1	39

206	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. *Atherosclerosis Supplements*, **2017**, 26, 16-24	1.7	15
205	Differences in Cardiac Structure and Function Between Black and White Patients: Another Step in the Evaluation of Cardiovascular Risk in Chronic Kidney Disease. *American Journal of Hypertension*, **2017**, 30, 770-771	2.3	1
204	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. *Atherosclerosis*, **2017**, 262, 179-184	3.1	14
203	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). *Atherosclerosis Supplements*, **2017**, 29, 11-16	1.7	38
202	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. *Atherosclerosis Supplements*, **2017**, 29, 17-24	1.7	45
201	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat Cells. Direct Effect of Oxidative Stress. *Scientific Reports*, **2017**, 7, 11863	4.9	41
200	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. *Circulation*, **2017**, 136, 332-335	16.7	63
199	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3340-3348	5.6	18
198	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. *Journal of Clinical Lipidology*, **2017**, 11, 1234-1242	4.9	19
197	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. *Acta Diabetologica*, **2017**, 54, 111-122	3.9	14
196	Inverse association between type 2 diabetes and aortic root dimension in hypertensive patients. *International Journal of Cardiology*, **2017**, 228, 233-237	3.2	6
195	Under-prescription of statins in patients with non-alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 161-167	4.5	32
194	The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. *Atherosclerosis*, **2017**, 262, 146-153	3.1	12
193	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. *European Heart Journal Supplements*, **2017**, 19, D3-D54	1.5	11
192	Baseline metabolic disturbances and the twenty-five years risk of incident cancer in a Mediterranean population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 1020-1025	4.5	14
191	Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up. *Indian Journal of Gastroenterology*, **2016**, 35, 236-41	1.9	7
190	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 36-44	4.5	11
189	Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2016**, 1861, 371-9	5	4

188	Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model. *Atherosclerosis*, **2016**, 246, 50-6	3.1	13
187	Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitis. *Transfusion*, **2016**, 56, 755-60	2.9	5
186	FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheimer disease. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 2215-26	4.4	3
185	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. *Atherosclerosis*, **2016**, 244, 138-46	3.1	150
184	Lomitapide affects HDL composition and function. *Atherosclerosis*, **2016**, 251, 15-18	3.1	6
183	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 1647-50	9.4	19
182	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *New England Journal of Medicine*, **2015**, 372, 1489-99	59.2	1347
181	Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. *Journal of Clinical Lipidology*, **2015**, 9, 607-17	4.9	37
180	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. *Atherosclerosis*, **2015**, 240, 408-14	3.1	31
179	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *European Heart Journal*, **2015**, 36, 2425-37	9.5	430
178	Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2694-9	9.4	17
177	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. *European Journal of Human Genetics*, **2015**, 23, 381-7	5.3	10
176	Issues Affecting Quality of Life and Disease Burden in Lipoprotein Lipase Deficiency (Lpld) First Step Towards a Pro Measure in Lpld. *Value in Health*, **2015**, 18, A707	3.3	4
175	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients. *Hemodialysis International*, **2015**, 19, 360-7	1.7	4
174	Role of Nutraceuticals in Hypolipidemic Therapy. *Frontiers in Cardiovascular Medicine*, **2015**, 2, 22	5.4	14
173	The pathophysiology of intestinal lipoprotein production. *Frontiers in Physiology*, **2015**, 6, 61	4.6	18
172	Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. *Atherosclerosis*, **2015**, 241, 79-86	3.1	43
171	The effect of ezetimibe on NAFLD. *Atherosclerosis Supplements*, **2015**, 17, 27-34	1.7	17

170	Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. *Atherosclerosis*, **2015**, 239, 209-17	3.1	15
169	Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. *Scandinavian Journal of Gastroenterology*, **2015**, 50, 347-54	2.4	16
168	Exome sequencing in suspected monogenic dyslipidemias. *Circulation: Cardiovascular Genetics*, **2015**, 8, 343-50		36
167	Beyond statins: new lipid lowering strategies to reduce cardiovascular risk. *Current Atherosclerosis Reports*, **2014**, 16, 414	6	16
166	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. *Atherosclerosis Supplements*, **2014**, 15, 33-45	1.7	25
165	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 655-66	18.1	357
164	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. *Atherosclerosis Supplements*, **2014**, 15, 1-15	1.7	62
163	Behavior of the total antioxidant status in a group of subjects with metabolic syndrome. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2014**, 8, 166-9	8.9	5
162	Lipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome. *Oxidative Medicine and Cellular Longevity*, **2014**, 2014, 824756	6.7	14
161	Lomitapide: a novel drug for homozygous familial hypercholesterolemia. *Clinical Lipidology*, **2014**, 9, 19-32		8
160	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *European Heart Journal*, **2014**, 35, 2146-57	9.5	614
159	eNOS activation by HDL is impaired in genetic CETP deficiency. *PLoS ONE*, **2014**, 9, e95925	3.7	30
158	Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. *Atherosclerosis*, **2013**, 227, 342-8	3.1	106
157	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. *Acta Diabetologica*, **2013**, 50, 241-9	3.9	30
156	Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. *American Journal of Cardiology*, **2013**, 112, 1885-95	3	34
155	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. *Lancet, The*, **2013**, 381, 40-6	40	480
154	Oxidative status in nondiabetic middle-aged subjects with metabolic syndrome: preliminary data. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, e17-8	4.5	2
153	Protein oxidation in a group of subjects with metabolic syndrome. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2013**, 7, 38-41	8.9	10

152	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *European Heart Journal*, **2013**, 34, 3478-90a	9.5	1551
151	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. *Journal of Lipid Research*, **2013**, 54, 3481-90	6.3	55
150	The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. *Diabetes Care*, **2013**, 36, 2850-6	14.6	42
149	A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2021-5	9.4	59
148	Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. *Journal of the American Heart Association*, **2013**, 2, e000063	6	21
147	Familial combined hypolipidemia due to mutations in the ANGPTL3 gene. *Clinical Lipidology*, **2013**, 8, 81-95		4
146	Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome. *Journal of Investigative Medicine*, **2013**, 61, 978-83	2.9	27
145	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. *Cardiovascular Therapeutics*, **2012**, 30, 61-74	3.3	12
144	Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. *Journal of Translational Medicine*, **2012**, 10, 235	8.5	28
143	Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2012**, 6, 132-5	8.9	18
142	Clinical utility of novel biomarkers for cardiovascular disease risk stratification. *Internal and Emergency Medicine*, **2012**, 7 Suppl 3, S263-70	3.7	4
141	Statin therapy in patients with aortic stenosis after the ASTRONOMER trial: is there still any space?. *Internal and Emergency Medicine*, **2012**, 7 Suppl 1, S35-6	3.7	2
140	Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. *Acta Diabetologica*, **2012**, 49, 145-51	3.9	9
139	Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 805-9	9.4	62
138	Lipid and apoprotein composition of HDL in partial or complete CETP deficiency. *Current Vascular Pharmacology*, **2012**, 10, 422-31	3.3	6
137	A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. *Journal of the American College of Cardiology*, **2011**, 58, 629-36	15.1	73
136	Plasma non-cholesterol sterols in primary hypobetalipoproteinemia. *Atherosclerosis*, **2011**, 216, 409-13	3.1	6
135	Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia. *Annals of Hepatology*, **2011**, 10, 221-226	3.1	14

134	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. *Combination Products in Therapy*, **2011**, 1, 1		2
133	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. *Clinical Biochemistry*, **2011**, 44, 627-34	3.5	2
132	Prevalence of "borderline" values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE study. *High Blood Pressure and Cardiovascular Prevention*, **2011**, 18, 43-51	2.9	3
131	Hypobetalipoproteinemia: Genetics, biochemistry, and clinical spectrum. *Advances in Clinical Chemistry*, **2011**, 54, 81-107	5.8	83
130	Lipase maturation factor 1 is required for endothelial lipase activity. *Journal of Lipid Research*, **2011**, 52, 1162-1169	6.3	21
129	Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. *Diabetes and Vascular Disease Research*, **2011**, 8, 262-70	3.3	9
128	Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. *Advances in Clinical Chemistry*, **2011**, 54, 81-107	5.8	30
127	Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. *Pediatric Research*, **2010**, 67, 200-4	3.2	13
126	Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. *Journal of Clinical Lipidology*, **2010**, 4, 272-8	4.9	10
125	The production of 85 kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apoB gene occurs by ALLN-inhibitable protease cleavage during translocation. *Biochemical and Biophysical Research Communications*, **2010**, 398, 665-70	3.4	5
124	A novel component of the metabolic syndrome: the oxidative stress. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 72-7	4.5	242
123	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. *Atherosclerosis*, **2010**, 208, 177-82	3.1	67
122	Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. *Lipids in Health and Disease*, **2010**, 9, 127	4.4	4
121	Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. *Metabolism: Clinical and Experimental*, **2010**, 59, 463-7	12.7	20
120	Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 828-37	15.4	62
119	A novel putative interactor for the low density lipoprotein receptor cytoplasmic domain. *Molecular Medicine Reports*, **2010**, 3, 341-5	2.9	
118	Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4584-90	5.6	45
117	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. *International Journal of Clinical Practice*, **2009**, 63, 547-59	2.9	57

116	C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. *Clinical Biochemistry*, **2009**, 42, 1713-8	3.5	27
115	Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 321-6	4.5	9
114	Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 84-90	4.5	60
113	Down regulation of CD11b and CD18 expression in children with hypercholesterolemia: a preliminary report. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 105-9	4.5	4
112	Obesity and the metabolic syndrome in a student cohort from Southern Italy. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 620-5	4.5	16
111	Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. *Atherosclerosis*, **2009**, 204, 202-7	3.1	24
110	Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. *Atherosclerosis*, **2009**, 206, 193-8	3.1	19
109	The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. *Atherosclerosis*, **2008**, 197, 147-53	3.1	38
108	A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 677-81	9.4	112
107	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. *Thrombosis and Haemostasis*, **2007**, 98, 1362-7	7	13
106	Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. *Journal of Internal Medicine*, **2007**, 262, 104-12	10.8	52
105	Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. *Free Radical Biology and Medicine*, **2007**, 43, 1255-62	7.8	97
104	Genetics of familial hypobetalipoproteinemia. *Future Lipidology*, **2007**, 2, 615-624		1
103	Molecular diagnosis of hypobetalipoproteinemia: an ENID review. *Atherosclerosis*, **2007**, 195, e19-27	3.1	133
102	The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. *Human Mutation*, **2006**, 27, 460-6	4.7	63
101	A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. *American Journal of Physiology - Renal Physiology*, **2006**, 290, G1170-6	5.1	13
100	Multiple food hypersensitivity as a cause of refractory chronic constipation in adults. *Scandinavian Journal of Gastroenterology*, **2006**, 41, 498-504	2.4	24
99	Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. *Atherosclerosis*, **2006**, 186, 433-40	3.1	82

98	CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol. *Atherosclerosis*, **2006**, 186, 225-7	3.1	3
97	Unexplained elevated serum pancreatic enzymes: a reason to suspect celiac disease. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 455-9	6.9	22
96	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. *Metabolism: Clinical and Experimental*, **2006**, 55, 662-8	12.7	15
95	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. *Metabolism: Clinical and Experimental*, **2006**, 55, 1308-16	12.7	13
94	Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study. *Journal of Alzheimer's Disease*, **2006**, 9, 273-8	4.3	32
93	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. *International Journal of Molecular Medicine*, **2006**, 18, 449	4.4	1
92	Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics. *Rapid Communications in Mass Spectrometry*, **2006**, 20, 2433-40	2.2	31
91	Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. *Acta Psychiatrica Scandinavica*, **2006**, 113, 59-63	6.5	30
90	Gene expression in mouse spermatogenesis during ontogenesis. *International Journal of Molecular Medicine*, **2006**, 17, 523-8	4.4	5
89	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. *International Journal of Molecular Medicine*, **2006**, 17, 539-46	4.4	4
88	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. *International Journal of Molecular Medicine*, **2006**, 18, 449-55	4.4	7
87	Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. *Atherosclerosis*, **2005**, 180, 311-8	3.1	53
86	Chronic constipation and food intolerance: a model of proctitis causing constipation. *Scandinavian Journal of Gastroenterology*, **2005**, 40, 33-42	2.4	37
85	Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. *International Journal of Cardiology*, **2005**, 101, 213-7	3.2	24
84	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2005**, 15, 361-7	4.5	8
83	Gastrointestinal symptoms in infancy: a population-based prospective study. *Digestive and Liver Disease*, **2005**, 37, 432-8	3.3	118
82	A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily. *British Journal of Dermatology*, **2005**, 153, 1019-22	4	16
81	No association between the cystatin C gene polymorphism and Alzheimer's disease: a case-control study in an Italian population. *Journal of Alzheimer's Disease*, **2005**, 7, 291-5	4.3	10

80	A novel mutation of the DHCR7 gene in a sicilian compound heterozygote with Smith-Lemli-Opitz Syndrome. *Molecular Diagnosis and Therapy*, **2005**, 9, 201-4		4
79	Anti-actin antibodies in celiac disease: correlation with intestinal mucosa damage and comparison of ELISA with the immunofluorescence assay. *Clinical Chemistry*, **2005**, 51, 917-20	5.5	23
78	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome **2005**, 9, 201		2
77	A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *JAMA - Journal of the American Medical Association*, **2004**, 291, 2221-8	27.4	197
76	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. *European Journal of Endocrinology*, **2004**, 150, 831-6	6.5	
75	Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. *International Journal of Biochemistry and Cell Biology*, **2004**, 36, 1297-305	5.6	6
74	Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. *Atherosclerosis*, **2004**, 172, 309-20	3.1	33
73	Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. *Atherosclerosis*, **2004**, 174, 57-65	3.1	68
72	Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. *Clinical Chemistry*, **2003**, 49, 861-7	5.5	154
71	Autoimmune enteropathy and colitis in an adult patient. *Digestive Diseases and Sciences*, **2003**, 48, 1600-6	4	43
70	Screening for celiac disease in non-Hodgkin lymphoma patients: a serum anti-transglutaminase-based approach. *Digestive Diseases and Sciences*, **2003**, 48, 1530-6	4	10
69	The C(-260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction. *Clinical and Experimental Medicine*, **2003**, 3, 161-5	4.9	21
68	Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. *Atherosclerosis*, **2003**, 166, 395-400	3.1	21
67	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. *Clinica Chimica Acta*, **2003**, 328, 91-7	6.2	1
66	No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer disease. *Neuroscience Letters*, **2003**, 341, 229-32	3.3	25
65	Two Italian kindreds carrying the Arg136-->Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele. *Nutrition, Metabolism and Cardiovascular Diseases*, **2003**, 13, 93-9	4.5	8
64	Statins and metabolic syndrome. *International Congress Series*, **2003**, 1253, 243-246		3
63	Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. *Blood Cells, Molecules, and Diseases*, **2003**, 31, 57-62	2.1	13

62	Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. *Journal of Lipid Research*, **2003**, 44, 470-8	6.3	111
61	Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up. *Thrombosis and Haemostasis*, **2002**, 87, 206-210	7	21
60	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. *American Journal of Cardiology*, **2002**, 89, 460-2	3	14
59	Nutritional characteristics of a rural Southern Italy population: the Ventimiglia di Sicilia Project. *Journal of the American College of Nutrition*, **2002**, 21, 523-9	3.5	22
58	Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer disease. *Neuroscience Letters*, **2002**, 335, 147-9	3.3	35
57	Comparison of Anti-Transglutaminase ELISAs and an Anti-Endomysial Antibody Assay in the Diagnosis of Celiac Disease: A Prospective Study. *Clinical Chemistry*, **2002**, 48, 1546-1550	5.5	97
56	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. *Journal of Lipid Research*, **2002**, 43, 407-415	6.3	22
55	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. *Journal of Lipid Research*, **2002**, 43, 407-15	6.3	21
54	Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. *Clinical Chemistry*, **2002**, 48, 1546-50	5.5	29
53	Determinants of enhanced thromboxane biosynthesis in renal transplantation. *Kidney International*, **2001**, 59, 1574-9	9.9	18
52	ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. *European Journal of Epidemiology*, **2001**, 17, 707-13	12.1	20
51	Estrogen increases hepatic lipase levels in inbred strains of mice: a possible mechanism for estrogen-dependent lowering of high density lipoprotein. *Molecular and Cellular Biochemistry*, **2001**, 220, 87-93	4.2	16
50	Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. *International Journal of Obesity*, **2001**, 25, 185-90	5.5	37
49	Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms. *International Journal of Biochemistry and Cell Biology*, **2001**, 33, 1215-26	5.6	6
48	Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up. *Atherosclerosis*, **2001**, 157, 225-31	3.1	31
47	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. *FEBS Journal*, **2000**, 267, 4272-80		43
46	A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides. *Journal of Biological Chemistry*, **2000**, 275, 32807-15	5.4	62
45	Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, E41-52	9.4	95

44	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism **2000**, 267, 4272		1
43	Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. *Kidney International*, **1999**, 55, 2433-9	9.9	12
42	Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. *Molecular and Cellular Biochemistry*, **1999**, 202, 37-46	4.2	14
41	Rapid screening of the LDL receptor point mutation FH-Genoa/Palermo. Mutation in brief no. 238. Online. *Human Mutation*, **1999**, 13, 412	4.7	1
40	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. *Journal of Lipid Research*, **1999**, 40, 901-912	6.3	11
39	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. *Journal of Lipid Research*, **1999**, 40, 955-959	6.3	29
38	Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins. *Transplantation*, **1999**, 67, 366-71	1.8	30
37	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. *Journal of Lipid Research*, **1999**, 40, 901-12	6.3	11
36	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. *Journal of Lipid Research*, **1999**, 40, 955-9	6.3	26
35	Lipoprotein profile and high-density lipoproteins: subfractions distribution in centenarians. *Gerontology*, **1998**, 44, 106-10	5.5	18
34	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. *Clinical Chemistry*, **1998**, 44, 1388-1396	5.5	19
33	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. *Clinical Chemistry*, **1998**, 44, 1388-96	5.5	3
32	Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway. *Journal of Biological Chemistry*, **1997**, 272, 33360-6	5.4	144
31	Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation. *Metabolism: Clinical and Experimental*, **1997**, 46, 1095-100	12.7	6
30	Liver is not the unique site of synthesis of beta 2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization. *International Journal of Clinical and Laboratory Research*, **1997**, 27, 207-12		25
29	A new apolipoprotein B truncation (apo B-43.7) in familial hypobetalipoproteinemia: genetic and metabolic studies. *Metabolism: Clinical and Experimental*, **1996**, 45, 1296-304	12.7	14
28	HDL subfractions distribution in renal transplant recipients: lack of evidence of a reduction of HDL2 particles. *Nephron*, **1996**, 72, 407-12	3.3	4
27	Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 247-51	9.4	205

26	Familial hypobetalipoproteinemia is not associated with low levels of lipoprotein(a). *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 2165-75	9.4	13
25	Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: effects of L-thyroxine substitution therapy. *Metabolism: Clinical and Experimental*, **1995**, 44, 1283-7	12.7	9
24	Plasma lipid, apolipoprotein and Lp(a) levels in elderly normolipidemic women: relationships with coronary heart disease and longevity. *Gerontology*, **1995**, 41, 260-6	5.5	21
23	Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia. *Journal of Clinical Apheresis*, **1995**, 10, 96-100	3.2	7
22	Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia. *Thrombosis and Haemostasis*, **1995**, 74, 1015-1019	7	25
21	Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. *Thrombosis and Haemostasis*, **1995**, 74, 1015-9	7	5
20	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. *Clinica Chimica Acta* , **1994**, 224, 111-8	6.2	6
19	Effects of gemfibrozil in hyperlipidemic patients with or without diabetes. *Current Therapeutic Research*, **1993**, 53, 381-393	2.4	2
18	Transient neonatal hypercholesterolemia. Lack of relationships with dehydroepiandrosterone sulfate. *Hormone and Metabolic Research*, **1993**, 25, 271-4	3.1	1
17	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48. *Journal of Lipid Research*, **1993**, 34, 1957-67	6.3	18
16	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48.. *Journal of Lipid Research*, **1993**, 34, 1957-1967	6.3	19
15	Increased thromboxane biosynthesis in type IIa hypercholesterolemia. *Circulation*, **1992**, 85, 1792-8	16.7	158
14	Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. *Digestive Diseases and Sciences*, **1992**, 37, 1441-6	4	55
13	Thrombin-antithrombin III complexes in type II diabetes mellitus. *Journal of Diabetes and Its Complications*, **1992**, 6, 7-11	3.2	25
12	Follow-up of lipid and apoprotein levels in renal transplant recipients. *Nephron*, **1991**, 58, 255-6	3.3	8
11	Apolipoprotein profile in type II diabetic patients with and without coronary heart disease. *Acta Diabetologica Latina*, **1990**, 27, 371-7		9
10	Thromboxane biosynthesis and platelet function in type II diabetes mellitus. *New England Journal of Medicine*, **1990**, 322, 1769-74	59.2	487
9	Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. *Atherosclerosis*, **1989**, 79, 79-83	3.1	41

8	Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: a comparison with type IV hyperlipoproteinemic patients. *Metabolism: Clinical and Experimental*, **1989**, 38, 601-2	12.7	16
7	Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic control. *Diabetes Research*, **1989**, 10, 7-12		14
6	Diagnostic use of fructosamine assay in the control of type II diabetes mellitus. *Acta Diabetologica Latina*, **1988**, 25, 63-8		2
5	Platelet activation after adrenergic stimulation in hypertensive patients: effects of acebutolol. *European Heart Journal*, **1983**, 4, 295-9	9.5	6
4	Correlation between different degree and duration of metabolic control and thyroid hormone levels in type 1 and type 2 diabetics. *Acta Diabetologica Latina*, **1983**, 20, 341-6		
3	Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. *Thrombosis Research*, **1982**, 26, 359-70	8.2	70
2	Enhanced platelet release reaction in insulin-dependent and insulin-independent diabetic patients. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1982**, 12, 275-81		6
1	Platelet Sensitivity to Prostacyclin and Thromboxane Production in Hyperlipidemic Patients. *Thrombosis and Haemostasis*, **1982**, 48, 018-020	7	54